Barclays lowered the firm’s price target on Humana to $364 from $370 and keeps an Equal Weight rating on the shares post the Q2 report. The analyst says developing inpatients trends in Q2 offset 2024 upside and tempered the 2025 outlook.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM: